Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitagliptin add-on to pioglitazone in T2DM
NCT00372060Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2006
- Primary completion
- Feb 2008
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing Sitagliptin + Pioglitazone with Placebo/Sitagliptin + Pioglitazone (2 arms). Primary endpoint: Change From Baseline in Hemoglobin A1c at 12 weeks. Started Aug 2006; status: completed.
02
Drugs
sitagliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT00372060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00372060.